University of Hertfordshire

Tools to study and target the Siglec–sialic acid axis in cancer

Research output: Contribution to journalReview articlepeer-review

Standard

Tools to study and target the Siglec–sialic acid axis in cancer. / Läubli, Heinz ; Kawanishi, Kunio ; Vazhappilly , Cijo George ; Matar, Rachel ; Merheb, Maxime ; Siddiqui, Shoib.

In: FEBS Journal, 21.12.2020.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Läubli, Heinz ; Kawanishi, Kunio ; Vazhappilly , Cijo George ; Matar, Rachel ; Merheb, Maxime ; Siddiqui, Shoib. / Tools to study and target the Siglec–sialic acid axis in cancer. In: FEBS Journal. 2020.

Bibtex

@article{6314feffd88e4065bbe74557ee467066,
title = "Tools to study and target the Siglec–sialic acid axis in cancer",
abstract = "Siglecs are widely expressed on leucocytes and bind to ubiquitously presented glycans containing sialic acids (sialoglycans). Most Siglecs carry an immunoreceptor tyrosine‐based inhibition motif (ITIM) and elicit an inhibitory intracellular signal upon ligand binding. A few Siglec receptors can, however, recruit immunoreceptor tyrosine‐based activation motif (ITAM)‐containing factors, which activate cells. The role of hypersialylation (the enhanced expression of sialoglycans) has recently been explored in cancer progression. Mechanistic studies have shown that hypersialylation on cancer cells can engage inhibitory Siglecs on the surface of immune cells and induce immunosuppression. These recent studies strongly suggest that the Siglec–sialic acid axis can act as a potential target for cancer immunotherapy. Moreover, the use of new tools and techniques is facilitating these studies. In this review, we summarise techniques used to study Siglecs, including different mouse models, monoclonal antibodies, Siglec fusion proteins, and sialoglycan arrays. Furthermore, we discuss the recent major developments in the study of Siglecs in cancer immunosuppression, tools, and techniques used in targeting the Siglec–sialic acid axis and the possibility of clinical intervention.",
author = "Heinz L{\"a}ubli and Kunio Kawanishi and Vazhappilly, {Cijo George} and Rachel Matar and Maxime Merheb and Shoib Siddiqui",
note = "{\textcopyright} 2020 Federation of European Biochemical Societies. ",
year = "2020",
month = dec,
day = "21",
doi = "10.1111/febs.15647",
language = "English",
journal = "FEBS Journal",
issn = "1742-464X",
publisher = "Wiley-Blackwell Publishing Ltd",

}

RIS

TY - JOUR

T1 - Tools to study and target the Siglec–sialic acid axis in cancer

AU - Läubli, Heinz

AU - Kawanishi, Kunio

AU - Vazhappilly , Cijo George

AU - Matar, Rachel

AU - Merheb, Maxime

AU - Siddiqui, Shoib

N1 - © 2020 Federation of European Biochemical Societies.

PY - 2020/12/21

Y1 - 2020/12/21

N2 - Siglecs are widely expressed on leucocytes and bind to ubiquitously presented glycans containing sialic acids (sialoglycans). Most Siglecs carry an immunoreceptor tyrosine‐based inhibition motif (ITIM) and elicit an inhibitory intracellular signal upon ligand binding. A few Siglec receptors can, however, recruit immunoreceptor tyrosine‐based activation motif (ITAM)‐containing factors, which activate cells. The role of hypersialylation (the enhanced expression of sialoglycans) has recently been explored in cancer progression. Mechanistic studies have shown that hypersialylation on cancer cells can engage inhibitory Siglecs on the surface of immune cells and induce immunosuppression. These recent studies strongly suggest that the Siglec–sialic acid axis can act as a potential target for cancer immunotherapy. Moreover, the use of new tools and techniques is facilitating these studies. In this review, we summarise techniques used to study Siglecs, including different mouse models, monoclonal antibodies, Siglec fusion proteins, and sialoglycan arrays. Furthermore, we discuss the recent major developments in the study of Siglecs in cancer immunosuppression, tools, and techniques used in targeting the Siglec–sialic acid axis and the possibility of clinical intervention.

AB - Siglecs are widely expressed on leucocytes and bind to ubiquitously presented glycans containing sialic acids (sialoglycans). Most Siglecs carry an immunoreceptor tyrosine‐based inhibition motif (ITIM) and elicit an inhibitory intracellular signal upon ligand binding. A few Siglec receptors can, however, recruit immunoreceptor tyrosine‐based activation motif (ITAM)‐containing factors, which activate cells. The role of hypersialylation (the enhanced expression of sialoglycans) has recently been explored in cancer progression. Mechanistic studies have shown that hypersialylation on cancer cells can engage inhibitory Siglecs on the surface of immune cells and induce immunosuppression. These recent studies strongly suggest that the Siglec–sialic acid axis can act as a potential target for cancer immunotherapy. Moreover, the use of new tools and techniques is facilitating these studies. In this review, we summarise techniques used to study Siglecs, including different mouse models, monoclonal antibodies, Siglec fusion proteins, and sialoglycan arrays. Furthermore, we discuss the recent major developments in the study of Siglecs in cancer immunosuppression, tools, and techniques used in targeting the Siglec–sialic acid axis and the possibility of clinical intervention.

U2 - 10.1111/febs.15647

DO - 10.1111/febs.15647

M3 - Review article

JO - FEBS Journal

JF - FEBS Journal

SN - 1742-464X

ER -